A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from PROSTAGLANDIN ENDOPEROXIDES in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension (HYPERTENSION, PULMONARY).
Increased VASCULAR RESISTANCE in the PULMONARY CIRCULATION, usually secondary to HEART DISEASES or LUNG DISEASES.
Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS.
The process of keeping pharmaceutical products in an appropriate location.
An eicosanoid, derived from the cyclooxygenase pathway of arachidonic acid metabolism. It is a stable and synthetic analog of EPOPROSTENOL, but with a longer half-life than the parent compound. Its actions are similar to prostacyclin. Iloprost produces vasodilation and inhibits platelet aggregation.
The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it.
Delivery of substances through VENIPUNCTURE into the VEINS.
Pathological process resulting in the fibrous obstruction of the small- and medium-sized PULMONARY VEINS and PULMONARY HYPERTENSION. Veno-occlusion can arise from fibrous proliferation of the VASCULAR INTIMA and VASCULAR MEDIA; THROMBOSIS; or a combination of both.
The movement and the forces involved in the movement of the blood through the CARDIOVASCULAR SYSTEM.
A vasodilator that apparently has direct actions on blood vessels and also increases cardiac output. Tolazoline can interact to some degree with histamine, adrenergic, and cholinergic receptors, but the mechanisms of its therapeutic effects are not clear. It is used in treatment of persistent pulmonary hypertension of the newborn.
The exercise capacity of an individual as measured by endurance (maximal exercise duration and/or maximal attained work load) during an EXERCISE TEST.
Substances added to pharmaceutical preparations to protect them from chemical change or microbial action. They include ANTI-BACTERIAL AGENTS and antioxidants.
Sulfones are a class of organic compounds containing the functional group with a sulfur atom bonded to two oxygen atoms and another organic group, widely used in pharmaceuticals, particularly for the treatment of bacterial infections, leprosy, and certain types of cancer.
A dull red, firm, dome-shaped hemangioma, sharply demarcated from surrounding skin, usually located on the head and neck, which grows rapidly and generally undergoes regression and involution without scarring. It is caused by proliferation of immature capillary vessels in active stroma, and is usually present at birth or occurs within the first two or three months of life. (Dorland, 27th ed)
Drugs used to cause dilation of the blood vessels.
The simultaneous, or near simultaneous, transference of heart and lungs from one human or animal to another.
A series of heterocyclic compounds that are variously substituted in nature and are known also as purine bases. They include ADENINE and GUANINE, constituents of nucleic acids, as well as many alkaloids such as CAFFEINE and THEOPHYLLINE. Uric acid is the metabolic end product of purine metabolism.
The force that opposes the flow of BLOOD through a vascular bed. It is equal to the difference in BLOOD PRESSURE across the vascular bed divided by the CARDIAC OUTPUT.
The circulation of the BLOOD through the LUNGS.
A group of compounds that contain the structure SO2NH2.
A coumarin that is used as an anticoagulant. Its actions and uses are similar to those of WARFARIN. (From Martindale, The Extra Pharmacopoeia, 30th ed, p233)
The short wide vessel arising from the conus arteriosus of the right ventricle and conveying unaerated blood to the lungs.
The blood pressure as recorded after wedging a CATHETER in a small PULMONARY ARTERY; believed to reflect the PRESSURE in the pulmonary CAPILLARIES.
The chemical and physical integrity of a pharmaceutical product.
Abnormalities in any part of the HEART SEPTUM resulting in abnormal communication between the left and the right chambers of the heart. The abnormal blood flow inside the heart may be caused by defects in the ATRIAL SEPTUM, the VENTRICULAR SEPTUM, or both.
Abnormal increase of resistance to blood flow within the hepatic PORTAL SYSTEM, frequently seen in LIVER CIRRHOSIS and conditions with obstruction of the PORTAL VEIN.
Chemistry dealing with the composition and preparation of agents having PHARMACOLOGIC ACTIONS or diagnostic use.
The administration of liquid medication, nutrient, or other fluid through some other route than the alimentary canal, usually over minutes or hours, either by gravity flow or often by infusion pumping.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Usually inert substances added to a prescription in order to provide suitable consistency to the dosage form. These include binders, matrix, base or diluent in pills, tablets, creams, salves, etc.
The transference of either one or both of the lungs from one human or animal to another.
Piperazines are a class of heterocyclic organic compounds containing a seven-membered ring with two nitrogen atoms at positions 1 and 4, often used in pharmaceuticals as smooth muscle relaxants, antipsychotics, antidepressants, and antihistamines, but can also be found as recreational drugs with stimulant and entactogen properties.
PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS.
A heterogeneous group of disorders, some hereditary, others acquired, characterized by abnormal structure or function of one or more of the elements of connective tissue, i.e., collagen, elastin, or the mucopolysaccharides.
Duration of blood flow after skin puncture. This test is used as a measure of capillary and platelet function.
A group of compounds derived from unsaturated 20-carbon fatty acids, primarily arachidonic acid, via the cyclooxygenase pathway. They are extremely potent mediators of a diverse group of physiological processes.
Therapy with two or more separate preparations given for a combined effect.
The attachment of PLATELETS to one another. This clumping together can be induced by a number of agents (e.g., THROMBIN; COLLAGEN) and is part of the mechanism leading to the formation of a THROMBUS.
The volume of BLOOD passing through the HEART per unit of time. It is usually expressed as liters (volume) per minute so as not to be confused with STROKE VOLUME (volume per beat).
The administration of drugs by the respiratory route. It includes insufflation into the respiratory tract.
Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.
Injections made into a vein for therapeutic or experimental purposes.
Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.
The relationship between the dose of an administered drug and the response of the organism to the drug.
Azoles with an OXYGEN and a NITROGEN next to each other at the 1,2 positions, in contrast to OXAZOLES that have nitrogens at the 1,3 positions.
Cell surface receptors for EPOPROSTENOL. They are coupled to HETEROTRIMERIC G-PROTEINS.
Regional infusion of drugs via an arterial catheter. Often a pump is used to impel the drug through the catheter. Used in therapy of cancer, upper gastrointestinal hemorrhage, infection, and peripheral vascular disease.
Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience.
The hemodynamic and electrophysiological action of the right HEART VENTRICLE.
Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals.
Adenosine 5'-(trihydrogen diphosphate). An adenine nucleotide containing two phosphate groups esterified to the sugar moiety at the 5'-position.
Agents that prevent clotting.
Blocking of the PULMONARY ARTERY or one of its branches by an EMBOLUS.
The giving of drugs, chemicals, or other substances by mouth.
Radiography of blood vessels after injection of a contrast medium.
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
## I'm sorry for any confusion, but "Japan" is not a medical term or concept. It is a country located in Asia, known as Nihon-koku or Nippon-koku in Japanese, and is renowned for its unique culture, advanced technology, and rich history. If you have any questions related to medical topics, I would be happy to help answer them!
The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.

Loss of endothelium and receptor-mediated dilation in pial arterioles of rats fed a short-term high salt diet. (1/157)

A high salt diet often is regarded as an accessory risk factor in hypertension, coincidental to the deleterious effect of high blood pressure on vasodilator function. The aim of this study was to determine whether short-term ingestion of a high salt diet per se impairs vasodilator function in the cerebral circulation independent of blood pressure changes. Adult Sprague-Dawley rats were fed a normal salt (0.8%) or high salt (4%) diet for 3 days. Mean arterial pressures were similar in the normal and high salt groups (123+/-2 and 125+/-2 mm Hg, respectively). Subsequently, the responses of the in situ pial arterioles to acetylcholine, iloprost, and sodium nitroprusside were determined in cranial windows using intravital videomicroscopy. Pial arterioles of rats fed normal and high salt diets showed similar resting diameters of 69+/-2 and 72+/-3 microm, respectively, but their reactivity patterns to vasodilator stimuli were markedly different. Arterioles of rats fed a normal salt diet dilated progressively up to 17+/-3% in response to the endothelium-dependent agent acetylcholine (10(-9) to 10(-6) mol/L) and dilated by 22+/-2% in response to the prostaglandin I2 receptor agonist iloprost (3x10(-11) mol/L). In contrast, pial arterioles of rats fed a high salt diet constricted by 4+/-3% and 8+/-2% in response to acetylcholine and iloprost, respectively. Sodium nitroprusside (10(-6) mol/L), a nitric oxide donor, dilated pial arterioles of rats fed low and high salt diets by a similar amount (19+/-3% and 16+/-2%, respectively), suggesting that signaling mechanisms for dilation distal to the vascular smooth muscle membrane were intact after high salt intake. These results provide the first evidence that the short-term ingestion of a high salt diet may severely impair the vasodilator function of the in situ cerebral microcirculation independent of blood pressure elevation.  (+info)

Platelet-stimulated thrombin and PDGF are normalized by insulin and Ca2+ channel blockers. (2/157)

Coronary artery disease is accelerated in chronic spinal cord injury (SCI). Because prostacyclin (PGI2) may retard atherogenesis through its inhibitory effects on platelet function, the role of PGI2 on SCI platelets was determined. The SCI platelets were neither hypersensitive to aggregating agonists nor resistant to the inhibitory effect of PGI2, but PGI2 failed to inhibit platelet-stimulated thrombin generation and the release of platelet-derived growth factor (PDGF) in SCI. Because thrombin and PDGF are atherogenic mitogens, the generation of these mitogens was investigated. Both the release of PDGF and thrombin generation in SCI platelets were higher when compared with control (n = 12). Treatment of non-SCI platelets with 100 nM PGE1 (a stable probe of PGI2) inhibited the release of the mitogens by 90% (P < 0.001), with no effect on SCI platelets. Scatchard analysis of prostaglandin E1 (PGE1) binding showed a 70% decrease of PGI2 receptors on the SCI platelet surface. Treatment of SCI platelets with insulin or Ca2+ channel blockers restored the PGI2-receptor number and "normalized" the inhibition of PDGF release and thrombin generation by PGI2.  (+info)

Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPARdelta. (3/157)

We have demonstrated previously that cyclo-oxygenase-2 (COX2), the rate-limiting enzyme in the biosynthesis of prostaglandins (PGs), is essential for blastocyst implantation and decidualization. However, the candidate PG(s) that participates in these processes and the mechanism of its action remain undefined. Using COX2-deficient mice and multiple approaches, we demonstrate herein that COX2-derived prostacyclin (PGI2) is the primary PG that is essential for implantation and decidualization. Several lines of evidence suggest that the effects of PGI2 are mediated by its activation of the nuclear hormone receptor PPARdelta, demonstrating the first reported biologic function of this receptor signaling pathway.  (+info)

Differential regulation of renal prostaglandin receptor mRNAs by dietary salt intake in the rat. (4/157)

BACKGROUND: In this study, we tested the hypothesis that prostaglandin (PG) receptor expression in the rat kidney is subject to physiological regulation by dietary salt intake. METHODS: Rats were fed diets with 0.02 or 4% NaCl for two weeks. PG receptor expression was assayed in kidney regions and cells by ribonuclease protection assay and reverse transcription-polymerase chain reaction analysis. Functional correlates were studied by measurement of PGE2-induced cAMP formation and renin secretion in juxtaglomerular (JG) cells isolated from animals on various salt intakes. RESULTS: EP1 and EP3 receptors were predominantly expressed, and the EP2 receptor was exclusively expressed in the rat kidney medulla. The EP4 receptor was strongly expressed in glomeruli and in renin-secreting JG granular cells. IP receptor transcripts were found mainly in cortex. Maintaining rats on a low- or high-NaCl diet did not affect the expression of EP1 or IP receptors, whereas EP4 transcripts in glomeruli were increased twofold by salt deprivation. Consistent with this, we found that PGE2-evoked cAMP production and renin secretion by JG cells from salt-deprived animals were significantly higher compared with cells obtained from salt-loaded animals. In the outer medulla, EP3 transcripts correlated directly with salt intake, and mRNA abundance was increased twofold by a high-NaCl diet. CONCLUSIONS: Our results suggest that subtype-specific, regional changes in PG receptor expression are involved in the renal adaptation to changes in salt intake. The results are in accord with the general concept that renocortical PGE2 stimulates renin secretion and maintains renal blood flow during low-salt states, whereas medullary PGE2 promotes salt excretion in response to a high salt intake.  (+info)

Altered gene expression of prostacyclin synthase and prostacyclin receptor in the thoracic aorta of spontaneously hypertensive rats. (5/157)

OBJECTIVE: The aim of this study was to evaluate the possible role of prostacyclin (PGI2) in the pathogenesis of hypertension in spontaneously hypertensive rats (SHR). METHODS: Measurement of mRNA and protein levels of PGH synthase (PGHS)-1, PGI2 synthase and the PGI2 receptor, in the thoracic aorta was performed in SHR aged 5, 10, 20, and 40 weeks old and in age-matched normotensive Wistar-Kyoto (WKY) rats with a competitive polymerase chain reaction method and immunoblotting. Aortic production of 6-keto-PGF1 alpha, the main metabolite of PGI2, was also measured. RESULTS: Compared with age-matched WKY rats, PGHS-1 mRNA and protein levels in the thoracic aorta of SHR increased with age, reaching three- and twofold higher than WKY rats at 40 weeks old, respectively. PGI2 synthase mRNA and protein levels in SHR were significantly higher than in WKY rats at 20 and 40 weeks old. In contrast, PGI2 receptor mRNA levels in SHR were consistently lower than in WKY rats at all ages. CONCLUSIONS: These results provide evidence that hypertension elicits alterations in levels of arachidonic acid metabolites, including PGH2 and PGI2. They also suggest that the decreased expression of PGI2 receptor mRNA in prehypertensive SHR could be one of the causes of hypertension in SHR.  (+info)

The prostacyclin receptor is isoprenylated. Isoprenylation is required for efficient receptor-effector coupling. (6/157)

The prostacyclin receptor (IP), a G protein-coupled receptor, mediates the actions of the prostanoid prostacyclin and its mimetics. IPs from a number of species each contain identically conserved putative isoprenylation CAAX motifs, each with the sequence CSLC. Metabolic labeling of human embryonic kidney (HEK) 293 cells stably overexpressing the hemagluttinin epitope-tagged IP in the presence of [(3)H]mevalonolactone established that the mouse IP is isoprenylated. Studies involving in vitro assays confirmed that recombinant forms of the human and mouse IP are modified by carbon 15 farnesyl isoprenoids. Disruption of isoprenylation, by site-directed mutagenesis of Cys(414) to Ser(414), within the CAAX motif, abolished isoprenylation of IP(SSLC) both in vitro and in transfected cells. Scatchard analysis of the wild type (IP) and mutant (IP(SSLC)) receptor confirmed that each receptor exhibited high and low affinity binding sites for [(3)H]iloprost, which were not influenced by receptor isoprenylation. Whereas stable cell lines overexpressing IP generated significant agonist (iloprost and cicaprost)-mediated increases in cAMP relative to nontransfected cells, cAMP generation by IP(SSLC) cells was not significantly different from the control, nontransfected HEK 293 cells. Moreover, co-expression of the alpha (alpha) subunit of Gs generated significant augmentations in cAMP by IP but not by IP(SSLC) cells. Whereas IP also demonstrated significant, dose-dependent increases in [Ca(2+)](i) in response to iloprost or cicaprost compared with the nontransfected HEK 293 cells, mobilization of [Ca(2+)](i) by IP(SSLC) was significantly impaired. Co-transfection of cells with either Galpha(q) or Galpha(11) resulted in significant augmentation of agonist-mediated [Ca(2+)](i) mobilization by IP cells but not by IP(SSLC) cells or by the control, HEK 293 cells. In addition, inhibition of isoprenylation by lovastatin treatment significantly reduced agonist-mediated cAMP generation by IP in comparison to the nonisoprenylated beta(2) adrenergic receptor or nontreated cells. Hence, isoprenylation of IP does not influence ligand binding but is required for efficient coupling to the effectors adenylyl cyclase and phospholipase C.  (+info)

Induction of prostaglandin I(2) receptor by tumor necrosis factor alpha in osteoblastic MC3T3-E1 cells. (7/157)

Mouse osteoblastic cells MC3T3-E1 produced prostaglandin E(2) via the reaction of cyclooxygenase-2 enzyme induced by tumor necrosis factor alpha (TNFalpha). Originally, the mRNA level for prostaglandin I(2) receptor (IP) was low in the cells. However, the addition of TNFalpha brought about a marked increase in the IP mRNA with a lag of about 3 h up to an about 8-fold higher level for 24 h. In addition, the induction of IP was supported by a binding experiment of [(3)H]iloprost (a stable analogue of prostaglandin I(2)). The amount of iloprost bound to the TNFalpha-stimulated cell membranes increased to a saturation level around 30 nM. Dexamethasone, cycloheximide and cyclooxygenase inhibitor suppressed the IP mRNA induction. The finding with the latter two compounds suggested a TNFalpha-dependent de novo synthesis of a protein, which is involved in the IP mRNA induction and may be attributed partially to the induced cyclooxygenase-2.  (+info)

cAMP production by piglet cerebral vascular smooth muscle cells: pH(o), pH(i), and permissive action of PGI(2). (8/157)

In newborn pig pial arterioles and cocultures of cerebral microvascular endothelial and smooth muscle cells, hypercapnia increases cAMP. In the intact cerebral circulation, both the increase in cAMP and the accompanying vasodilation require the presence of PGI(2). Using piglet cerebral microvascular smooth muscle in primary culture, we addressed the hypothesis that, in the presence of PGI(2), hypercapnia-induced changes in extracellular pH cause increases in cAMP. The stable PGI(2)-receptor agonist iloprost did increase production of cAMP in response to combined extracellular pH and pH(i) (11 +/- 6 vs. 32 +/- 10% in the absence and presence of 10(-10) M iloprost, respectively). However, there was no positive dose-response relationship between iloprost concentration and stimulation of cAMP production by acidosis (e.g., 58 +/- 9 vs. 41 +/- 5% in the presence of 10(-12) and 10(-9) M iloprost, respectively). Rapid decreases in pH(i) stimulate the cAMP production. Decreases in extracellular pH do not appear to contribute further. The G protein inhibitor pertussis toxin did not augment cAMP production in response to decreasing pH(i). We conclude that PGI(2) receptor activation permits another mechanism to enhance cAMP generation in response to intracellular, but not extracellular, acidosis and that the mechanism of the permissive effect of PGI(2) does not involve inhibition of a pertussis toxin-sensitive G protein.  (+info)

Epoprostenol is a medication that belongs to a class of drugs called prostaglandins. It is a synthetic analog of a natural substance in the body called prostacyclin, which widens blood vessels and has anti-platelet effects. Epoprostenol is used to treat pulmonary arterial hypertension (PAH), a condition characterized by high blood pressure in the arteries that supply blood to the lungs.

Epoprostenol works by relaxing the smooth muscle in the walls of the pulmonary arteries, which reduces the resistance to blood flow and lowers the pressure within these vessels. This helps improve symptoms such as shortness of breath, fatigue, and chest pain, and can also prolong survival in people with PAH.

Epoprostenol is administered continuously through a small pump that delivers the medication directly into the bloodstream. It is a potent vasodilator, which means it can cause a sudden drop in blood pressure if not given carefully. Therefore, it is usually started in a hospital setting under close medical supervision.

Common side effects of epoprostenol include headache, flushing, jaw pain, nausea, vomiting, diarrhea, and muscle or joint pain. More serious side effects can include bleeding, infection at the site of the catheter, and an allergic reaction to the medication.

Pulmonary hypertension is a medical condition characterized by increased blood pressure in the pulmonary arteries, which are the blood vessels that carry blood from the right side of the heart to the lungs. This results in higher than normal pressures in the pulmonary circulation and can lead to various symptoms and complications.

Pulmonary hypertension is typically defined as a mean pulmonary artery pressure (mPAP) greater than or equal to 25 mmHg at rest, as measured by right heart catheterization. The World Health Organization (WHO) classifies pulmonary hypertension into five groups based on the underlying cause:

1. Pulmonary arterial hypertension (PAH): This group includes idiopathic PAH, heritable PAH, drug-induced PAH, and associated PAH due to conditions such as connective tissue diseases, HIV infection, portal hypertension, congenital heart disease, and schistosomiasis.
2. Pulmonary hypertension due to left heart disease: This group includes conditions that cause elevated left atrial pressure, such as left ventricular systolic or diastolic dysfunction, valvular heart disease, and congenital cardiovascular shunts.
3. Pulmonary hypertension due to lung diseases and/or hypoxia: This group includes chronic obstructive pulmonary disease (COPD), interstitial lung disease, sleep-disordered breathing, alveolar hypoventilation disorders, and high altitude exposure.
4. Chronic thromboembolic pulmonary hypertension (CTEPH): This group includes persistent obstruction of the pulmonary arteries due to organized thrombi or emboli.
5. Pulmonary hypertension with unclear and/or multifactorial mechanisms: This group includes hematologic disorders, systemic disorders, metabolic disorders, and other conditions that can cause pulmonary hypertension but do not fit into the previous groups.

Symptoms of pulmonary hypertension may include shortness of breath, fatigue, chest pain, lightheadedness, and syncope (fainting). Diagnosis typically involves a combination of medical history, physical examination, imaging studies, and invasive testing such as right heart catheterization. Treatment depends on the underlying cause but may include medications, oxygen therapy, pulmonary rehabilitation, and, in some cases, surgical intervention.

Antihypertensive agents are a class of medications used to treat high blood pressure (hypertension). They work by reducing the force and rate of heart contractions, dilating blood vessels, or altering neurohormonal activation to lower blood pressure. Examples include diuretics, beta blockers, ACE inhibitors, ARBs, calcium channel blockers, and direct vasodilators. These medications may be used alone or in combination to achieve optimal blood pressure control.

"Drug storage" refers to the proper handling, maintenance, and preservation of medications in a safe and suitable environment to ensure their effectiveness and safety until they are used. Proper drug storage includes:

1. Protecting drugs from light, heat, and moisture: Exposure to these elements can degrade the quality and potency of medications. Therefore, it is recommended to store most drugs in a cool, dry place, away from direct sunlight.

2. Keeping drugs out of reach of children and pets: Medications should be stored in a secure location, such as a locked cabinet or medicine chest, to prevent accidental ingestion or harm to young children and animals.

3. Following storage instructions on drug labels and packaging: Some medications require specific storage conditions, such as refrigeration or protection from freezing. Always follow the storage instructions provided by the manufacturer or pharmacist.

4. Regularly inspecting drugs for signs of degradation or expiration: Check medications for changes in color, consistency, or odor, and discard any that have expired or show signs of spoilage.

5. Storing drugs separately from one another: Keep different medications separate to prevent cross-contamination, incorrect dosing, or accidental mixing of incompatible substances.

6. Avoiding storage in areas with high humidity or temperature fluctuations: Bathrooms, kitchens, and garages are generally not ideal for storing medications due to their exposure to moisture, heat, and temperature changes.

Proper drug storage is crucial for maintaining the safety, efficacy, and stability of medications. Improper storage can lead to reduced potency, increased risk of adverse effects, or even life-threatening situations. Always consult a healthcare professional or pharmacist for specific storage instructions and recommendations.

Iloprost is a synthetic analogue of prostacyclin, a naturally occurring substance in the body. It is a medication that belongs to a class of drugs called vasodilators, which work by relaxing and widening blood vessels. Iloprost is used to treat pulmonary arterial hypertension (PAH), a condition characterized by high blood pressure in the arteries that supply blood to the lungs. By dilating these blood vessels, iloprost helps reduce the workload on the heart and improve symptoms associated with PAH such as shortness of breath, fatigue, and dizziness.

Iloprost is administered through inhalation using a nebulizer, typically several times a day. It may also be used to prevent or treat episodes of digital ischemia, a condition that causes reduced blood flow to the fingers and toes, leading to pain and tissue damage.

It's important to note that while iloprost can help manage symptoms of PAH and digital ischemia, it does not cure these conditions. Close monitoring by a healthcare provider is necessary to ensure safe and effective use of this medication.

Intravenous (IV) infusion is a medical procedure in which liquids, such as medications, nutrients, or fluids, are delivered directly into a patient's vein through a needle or a catheter. This route of administration allows for rapid absorption and distribution of the infused substance throughout the body. IV infusions can be used for various purposes, including resuscitation, hydration, nutrition support, medication delivery, and blood product transfusion. The rate and volume of the infusion are carefully controlled to ensure patient safety and efficacy of treatment.

Intravenous (IV) administration is a medical procedure where medication or fluids are delivered directly into a vein. This method allows for rapid absorption and distribution of the substance throughout the body. It is commonly used to provide immediate treatment in emergency situations, administer medications that cannot be given by other routes, or deliver fluids and electrolytes when someone is dehydrated.

To perform an IV administration, a healthcare professional first prepares the necessary equipment, including a sterile needle or catheter, syringe, and the medication or fluid to be administered. The site of insertion is typically on the back of the hand, inner elbow, or forearm, where veins are more visible and accessible. After cleaning and disinfecting the skin, the healthcare professional inserts the needle or catheter into the vein, securing it in place with tape or a dressing. The medication or fluid is then slowly injected or infused through the IV line.

Possible risks associated with IV administration include infection, infiltration (when the fluid leaks into surrounding tissue instead of the vein), extravasation (when the medication leaks out of the vein and causes tissue damage), and phlebitis (inflammation of the vein). Proper technique and monitoring during and after IV administration can help minimize these risks.

Pulmonary Veno-Occlusive Disease (PVOD) is a rare form of pulmonary hypertension, characterized by the obstruction or blockage of the pulmonary veins. This obstruction can lead to increased pressure in the pulmonary circulation, ultimately causing right heart failure.

The medical definition of Pulmonary Veno-Occlusive Disease is: "A progressive and often fatal condition in which there is a selective occlusion or obliteration of the pulmonary venules and small veins, resulting in pulmonary hypertension, right ventricular failure, and death."

The obstruction of the pulmonary veins can be caused by various factors, including inflammation, fibrosis, or thrombosis. Symptoms of PVOD may include shortness of breath, fatigue, coughing up blood, and signs of right heart failure such as peripheral edema and ascites.

Diagnosis of PVOD can be challenging due to its rarity and nonspecific symptoms. Imaging studies, such as chest X-ray or CT scan, may show signs of pulmonary congestion and enlarged central pulmonary veins. A definitive diagnosis usually requires a lung biopsy.

Treatment options for PVOD are limited, and there is no cure for the disease. Currently, lung transplantation remains the only potentially curative treatment option for patients with PVOD.

Hemodynamics is the study of how blood flows through the cardiovascular system, including the heart and the vascular network. It examines various factors that affect blood flow, such as blood volume, viscosity, vessel length and diameter, and pressure differences between different parts of the circulatory system. Hemodynamics also considers the impact of various physiological and pathological conditions on these variables, and how they in turn influence the function of vital organs and systems in the body. It is a critical area of study in fields such as cardiology, anesthesiology, and critical care medicine.

Tolazoline is a medication that acts as an alpha-adrenergic antagonist and a weak peripheral vasodilator. It is primarily used in the treatment of digital ischemia, which is a lack of blood flow to the fingers or toes, often caused by diseases such as scleroderma or Raynaud's phenomenon. Tolazoline works by relaxing the blood vessels and improving blood flow to the affected areas.

It is important to note that the use of tolazoline is limited due to its potential for causing serious side effects, including hypotension (low blood pressure), tachycardia (rapid heart rate), and cardiac arrhythmias (irregular heart rhythms). Therefore, it should only be used under the close supervision of a healthcare provider.

Exercise tolerance is a term used to describe the ability of an individual to perform physical activity or exercise without experiencing symptoms such as shortness of breath, chest pain, or undue fatigue. It is often used as a measure of cardiovascular fitness and can be assessed through various tests, such as a stress test or a six-minute walk test. Exercise intolerance may indicate the presence of underlying medical conditions, such as heart disease, lung disease, or deconditioning.

Pharmaceutical preservatives are substances that are added to medications, pharmaceutical products, or biological specimens to prevent degradation, contamination, or spoilage caused by microbial growth, chemical reactions, or environmental factors. These preservatives help extend the shelf life and ensure the stability, safety, and efficacy of the pharmaceutical formulation during storage and use.

Commonly used pharmaceutical preservatives include:

1. Antimicrobials: These are further classified into antifungals (e.g., benzalkonium chloride, chlorhexidine, thimerosal), antibacterials (e.g., parabens, phenol, benzyl alcohol), and antivirals (e.g., phenolic compounds). They work by inhibiting the growth of microorganisms like bacteria, fungi, and viruses.
2. Antioxidants: These substances prevent or slow down oxidation reactions that can degrade pharmaceutical products. Examples include ascorbic acid (vitamin C), tocopherols (vitamin E), sulfites, and butylated hydroxyanisole (BHA) and butylated hydroxytoluene (BHT).
3. Chelating agents: These bind to metal ions that can catalyze degradation reactions in pharmaceutical products. Ethylenediaminetetraacetic acid (EDTA) is an example of a chelating agent used in pharmaceuticals.

The choice of preservative depends on the type of formulation, route of administration, and desired shelf life. The concentration of the preservative should be optimized to maintain product stability while minimizing potential toxicity or adverse effects. It is essential to conduct thorough safety and compatibility studies before incorporating any preservative into a pharmaceutical formulation.

Sulfones are a group of medications that contain a sulfur atom bonded to two oxygen atoms and one other group, typically a hydrogen or carbon atom. They have various medical uses, including as antibacterial, antifungal, and anti-inflammatory agents. One example of a sulfone is dapsone, which is used to treat bacterial infections such as leprosy and Pneumocystis jirovecii pneumonia (PJP), as well as some inflammatory skin conditions. It's important to note that sulfones can have significant side effects and should only be used under the supervision of a healthcare professional.

A capillary hemangioma is a benign (non-cancerous) vascular tumor that is made up of an overgrowth of small blood vessels called capillaries. These lesions are quite common and usually appear during the first few weeks or months of life, although they can also develop later in childhood or even in adulthood.

Capillary hemangiomas typically appear as a bright red, raised, and rubbery lesion on the skin. They may be small and localized, or they can grow and spread to cover a larger area of the body. In some cases, capillary hemangiomas may also form on internal organs such as the liver, brain, or gastrointestinal tract.

While capillary hemangiomas are generally harmless, they can cause cosmetic concerns if they appear on the face or other visible areas of the body. In some cases, these lesions may also interfere with vision, hearing, or other bodily functions if they grow too large or are located in sensitive areas.

Most capillary hemangiomas will eventually shrink and disappear on their own over time, typically within the first few years of life. However, in some cases, medical treatment may be necessary to help speed up this process or to address any complications that arise. Treatment options for capillary hemangiomas may include medications such as corticosteroids or beta-blockers, laser therapy, or surgical removal.

Vasodilator agents are pharmacological substances that cause the relaxation or widening of blood vessels by relaxing the smooth muscle in the vessel walls. This results in an increase in the diameter of the blood vessels, which decreases vascular resistance and ultimately reduces blood pressure. Vasodilators can be further classified based on their site of action:

1. Systemic vasodilators: These agents cause a generalized relaxation of the smooth muscle in the walls of both arteries and veins, resulting in a decrease in peripheral vascular resistance and preload (the volume of blood returning to the heart). Examples include nitroglycerin, hydralazine, and calcium channel blockers.
2. Arterial vasodilators: These agents primarily affect the smooth muscle in arterial vessel walls, leading to a reduction in afterload (the pressure against which the heart pumps blood). Examples include angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), and direct vasodilators like sodium nitroprusside.
3. Venous vasodilators: These agents primarily affect the smooth muscle in venous vessel walls, increasing venous capacitance and reducing preload. Examples include nitroglycerin and other organic nitrates.

Vasodilator agents are used to treat various cardiovascular conditions such as hypertension, heart failure, angina, and pulmonary arterial hypertension. It is essential to monitor their use carefully, as excessive vasodilation can lead to orthostatic hypotension, reflex tachycardia, or fluid retention.

Heart-lung transplantation is a surgical procedure where both the heart and lungs of a patient are replaced with those from a deceased donor. This complex and highly specialized surgery is typically considered as a last resort for patients suffering from end-stage lung or heart-lung diseases, such as cystic fibrosis, pulmonary fibrosis, chronic obstructive pulmonary disease (COPD), or certain forms of congenital heart disease, who have exhausted all other treatment options and face imminent death.

The procedure involves removing the patient's diseased heart and lungs en bloc, followed by implanting the donor's heart and lungs in their place. The surgery requires a skilled multidisciplinary team of cardiothoracic surgeons, anesthesiologists, perfusionists, transplant coordinators, and intensive care specialists.

Following the transplantation, patients require lifelong immunosuppressive therapy to prevent rejection of the transplanted organs. Despite the significant risks associated with this procedure, including infection, bleeding, and rejection, heart-lung transplantation can significantly improve both survival and quality of life for carefully selected patients with advanced heart-lung disease.

Purines are heterocyclic aromatic organic compounds that consist of a pyrimidine ring fused to an imidazole ring. They are fundamental components of nucleotides, which are the building blocks of DNA and RNA. In the body, purines can be synthesized endogenously or obtained through dietary sources such as meat, seafood, and certain vegetables.

Once purines are metabolized, they are broken down into uric acid, which is excreted by the kidneys. Elevated levels of uric acid in the body can lead to the formation of uric acid crystals, resulting in conditions such as gout or kidney stones. Therefore, maintaining a balanced intake of purine-rich foods and ensuring proper kidney function are essential for overall health.

Vascular resistance is a measure of the opposition to blood flow within a vessel or a group of vessels, typically expressed in units of mmHg/(mL/min) or sometimes as dynes*sec/cm^5. It is determined by the diameter and length of the vessels, as well as the viscosity of the blood flowing through them. In general, a decrease in vessel diameter, an increase in vessel length, or an increase in blood viscosity will result in an increase in vascular resistance, while an increase in vessel diameter, a decrease in vessel length, or a decrease in blood viscosity will result in a decrease in vascular resistance. Vascular resistance is an important concept in the study of circulation and cardiovascular physiology because it plays a key role in determining blood pressure and blood flow within the body.

Pulmonary circulation refers to the process of blood flow through the lungs, where blood picks up oxygen and releases carbon dioxide. This is a vital part of the overall circulatory system, which delivers nutrients and oxygen to the body's cells while removing waste products like carbon dioxide.

In pulmonary circulation, deoxygenated blood from the systemic circulation returns to the right atrium of the heart via the superior and inferior vena cava. The blood then moves into the right ventricle through the tricuspid valve and gets pumped into the pulmonary artery when the right ventricle contracts.

The pulmonary artery divides into smaller vessels called arterioles, which further branch into a vast network of tiny capillaries in the lungs. Here, oxygen from the alveoli diffuses into the blood, binding to hemoglobin in red blood cells, while carbon dioxide leaves the blood and is exhaled through the nose or mouth.

The now oxygenated blood collects in venules, which merge to form pulmonary veins. These veins transport the oxygen-rich blood back to the left atrium of the heart, where it enters the systemic circulation once again. This continuous cycle enables the body's cells to receive the necessary oxygen and nutrients for proper functioning while disposing of waste products.

Sulfonamides are a group of synthetic antibacterial drugs that contain the sulfonamide group (SO2NH2) in their chemical structure. They are bacteriostatic agents, meaning they inhibit bacterial growth rather than killing them outright. Sulfonamides work by preventing the bacteria from synthesizing folic acid, which is essential for their survival.

The first sulfonamide drug was introduced in the 1930s and since then, many different sulfonamides have been developed with varying chemical structures and pharmacological properties. They are used to treat a wide range of bacterial infections, including urinary tract infections, respiratory tract infections, skin and soft tissue infections, and ear infections.

Some common sulfonamide drugs include sulfisoxazole, sulfamethoxazole, and trimethoprim-sulfamethoxazole (a combination of a sulfonamide and another antibiotic called trimethoprim). While sulfonamides are generally safe and effective when used as directed, they can cause side effects such as rash, nausea, and allergic reactions. It is important to follow the prescribing physician's instructions carefully and to report any unusual symptoms or side effects promptly.

Acenocoumarol is an anticoagulant medication that is used to prevent and treat blood clots. It works by inhibiting the formation of vitamin K-dependent clotting factors, which are necessary for normal blood coagulation. This results in a prolonged bleeding time and reduced risk of blood clots.

Acenocoumarol is a coumarin derivative and is available under various brand names, including Sintrom and Nicoumalone. It is typically administered orally in the form of tablets and its effects are monitored through regular blood tests to ensure that the dosage is appropriate and that the risk of bleeding complications is minimized.

Common side effects of acenocoumarol include easy bruising, nosebleeds, and skin rashes. It may also interact with a variety of other medications, including antibiotics, antifungals, and certain herbal supplements, so it is important to inform your healthcare provider of all medications and supplements you are taking before starting acenocoumarol therapy.

It is important to note that acenocoumarol has a narrow therapeutic index, meaning that the difference between an effective dose and a toxic dose is relatively small. Therefore, it is essential to follow your healthcare provider's instructions carefully when taking this medication and to have regular blood tests to monitor its effects on your coagulation status.

The pulmonary artery is a large blood vessel that carries deoxygenated blood from the right ventricle of the heart to the lungs for oxygenation. It divides into two main branches, the right and left pulmonary arteries, which further divide into smaller vessels called arterioles, and then into a vast network of capillaries in the lungs where gas exchange occurs. The thin walls of these capillaries allow oxygen to diffuse into the blood and carbon dioxide to diffuse out, making the blood oxygen-rich before it is pumped back to the left side of the heart through the pulmonary veins. This process is crucial for maintaining proper oxygenation of the body's tissues and organs.

Pulmonary wedge pressure, also known as pulmonary capillary wedge pressure (PCWP) or left heart filling pressure, is a measurement obtained during right heart catheterization. It reflects the pressure in the left atrium, which is an estimate of the diastolic pressure in the left ventricle. Normal PCWP ranges from 4 to 12 mmHg. Increased pulmonary wedge pressure can indicate heart failure or other cardiac disorders that affect the left side of the heart.

Drug stability refers to the ability of a pharmaceutical drug product to maintain its physical, chemical, and biological properties during storage and use, under specified conditions. A stable drug product retains its desired quality, purity, strength, and performance throughout its shelf life. Factors that can affect drug stability include temperature, humidity, light exposure, and container compatibility. Maintaining drug stability is crucial to ensure the safety and efficacy of medications for patients.

A heart septal defect is a type of congenital heart defect, which means it is present at birth. It involves an abnormal opening in the septum, the wall that separates the two sides of the heart. This opening allows oxygen-rich blood to leak into the oxygen-poor blood chambers in the heart.

There are several types of heart septal defects, including:

1. Atrial Septal Defect (ASD): A hole in the atrial septum, the wall between the two upper chambers of the heart (the right and left atria).
2. Ventricular Septal Defect (VSD): A hole in the ventricular septum, the wall between the two lower chambers of the heart (the right and left ventricles).
3. Atrioventricular Septal Defect (AVSD): A combination of an ASD and a VSD, often accompanied by malformation of the mitral and/or tricuspid valves.

The severity of a heart septal defect depends on the size of the opening and its location in the septum. Small defects may cause no symptoms and may close on their own over time. Larger defects can lead to complications, such as heart failure, pulmonary hypertension, or infective endocarditis, and may require medical or surgical intervention.

Portal hypertension is a medical condition characterized by an increased pressure in the portal vein, which is the large blood vessel that carries blood from the intestines, spleen, and pancreas to the liver. Normal portal venous pressure is approximately 5-10 mmHg. Portal hypertension is defined as a portal venous pressure greater than 10 mmHg.

The most common cause of portal hypertension is cirrhosis of the liver, which leads to scarring and narrowing of the small blood vessels in the liver, resulting in increased resistance to blood flow. Other causes include blood clots in the portal vein, inflammation of the liver or bile ducts, and invasive tumors that block the flow of blood through the liver.

Portal hypertension can lead to a number of complications, including the development of abnormal blood vessels (varices) in the esophagus, stomach, and intestines, which are prone to bleeding. Ascites, or the accumulation of fluid in the abdominal cavity, is another common complication of portal hypertension. Other potential complications include encephalopathy, which is a condition characterized by confusion, disorientation, and other neurological symptoms, and an increased risk of bacterial infections.

Treatment of portal hypertension depends on the underlying cause and the severity of the condition. Medications to reduce pressure in the portal vein, such as beta blockers or nitrates, may be used. Endoscopic procedures to band or inject varices can help prevent bleeding. In severe cases, surgery or liver transplantation may be necessary.

Pharmaceutical chemistry is a branch of chemistry that deals with the design, synthesis, and development of chemical entities used as medications. It involves the study of drugs' physical, chemical, and biological properties, as well as their interactions with living organisms. This field also encompasses understanding the absorption, distribution, metabolism, and excretion (ADME) of drugs in the body, which are critical factors in drug design and development. Pharmaceutical chemists often work closely with biologists, medical professionals, and engineers to develop new medications and improve existing ones.

Parenteral infusions refer to the administration of fluids or medications directly into a patient's vein or subcutaneous tissue using a needle or catheter. This route bypasses the gastrointestinal tract and allows for rapid absorption and onset of action. Parenteral infusions can be used to correct fluid and electrolyte imbalances, administer medications that cannot be given orally, provide nutritional support, and deliver blood products. Common types of parenteral infusions include intravenous (IV) drips, IV push, and subcutaneous infusions. It is important that parenteral infusions are administered using aseptic technique to reduce the risk of infection.

Treatment outcome is a term used to describe the result or effect of medical treatment on a patient's health status. It can be measured in various ways, such as through symptoms improvement, disease remission, reduced disability, improved quality of life, or survival rates. The treatment outcome helps healthcare providers evaluate the effectiveness of a particular treatment plan and make informed decisions about future care. It is also used in clinical research to compare the efficacy of different treatments and improve patient care.

Excipients are inactive substances that serve as vehicles or mediums for the active ingredients in medications. They make up the bulk of a pharmaceutical formulation and help to stabilize, preserve, and enhance the delivery of the active drug compound. Common examples of excipients include binders, fillers, coatings, disintegrants, flavors, sweeteners, and colors. While excipients are generally considered safe and inert, they can sometimes cause allergic reactions or other adverse effects in certain individuals.

Lung transplantation is a surgical procedure where one or both diseased lungs are removed and replaced with healthy lungs from a deceased donor. It is typically considered as a treatment option for patients with end-stage lung diseases, such as chronic obstructive pulmonary disease (COPD), cystic fibrosis, idiopathic pulmonary fibrosis, and alpha-1 antitrypsin deficiency, who have exhausted all other medical treatments and continue to suffer from severe respiratory failure.

The procedure involves several steps, including evaluating the patient's eligibility for transplantation, matching the donor's lung size and blood type with the recipient, and performing the surgery under general anesthesia. After the surgery, patients require close monitoring and lifelong immunosuppressive therapy to prevent rejection of the new lungs.

Lung transplantation can significantly improve the quality of life and survival rates for some patients with end-stage lung disease, but it is not without risks, including infection, bleeding, and rejection. Therefore, careful consideration and thorough evaluation are necessary before pursuing this treatment option.

Piperazines are a class of heterocyclic organic compounds that contain a seven-membered ring with two nitrogen atoms at positions 1 and 4. They have the molecular formula N-NRR' where R and R' can be alkyl or aryl groups. Piperazines have a wide range of uses in pharmaceuticals, agrochemicals, and as building blocks in organic synthesis.

In a medical context, piperazines are used in the manufacture of various drugs, including some antipsychotics, antidepressants, antihistamines, and anti-worm medications. For example, the antipsychotic drug trifluoperazine and the antidepressant drug nefazodone both contain a piperazine ring in their chemical structure.

However, it's important to note that some piperazines are also used as recreational drugs due to their stimulant and euphoric effects. These include compounds such as BZP (benzylpiperazine) and TFMPP (trifluoromethylphenylpiperazine), which have been linked to serious health risks, including addiction, seizures, and death. Therefore, the use of these substances should be avoided.

Blood pressure is the force exerted by circulating blood on the walls of the blood vessels. It is measured in millimeters of mercury (mmHg) and is given as two figures:

1. Systolic pressure: This is the pressure when the heart pushes blood out into the arteries.
2. Diastolic pressure: This is the pressure when the heart rests between beats, allowing it to fill with blood.

Normal blood pressure for adults is typically around 120/80 mmHg, although this can vary slightly depending on age, sex, and other factors. High blood pressure (hypertension) is generally considered to be a reading of 130/80 mmHg or higher, while low blood pressure (hypotension) is usually defined as a reading below 90/60 mmHg. It's important to note that blood pressure can fluctuate throughout the day and may be affected by factors such as stress, physical activity, and medication use.

Connective tissue diseases (CTDs) are a group of disorders that involve the abnormal production and accumulation of abnormal connective tissues in various parts of the body. Connective tissues are the structural materials that support and bind other tissues and organs together. They include tendons, ligaments, cartilage, fat, and the material that fills the spaces between cells, called the extracellular matrix.

Connective tissue diseases can affect many different systems in the body, including the skin, joints, muscles, lungs, kidneys, gastrointestinal tract, and blood vessels. Some CTDs are autoimmune disorders, meaning that the immune system mistakenly attacks healthy connective tissues. Others may be caused by genetic mutations or environmental factors.

Some examples of connective tissue diseases include:

* Systemic lupus erythematosus (SLE)
* Rheumatoid arthritis (RA)
* Scleroderma
* Dermatomyositis/Polymyositis
* Mixed Connective Tissue Disease (MCTD)
* Sjogren's syndrome
* Ehlers-Danlos syndrome
* Marfan syndrome
* Osteogenesis imperfecta

The specific symptoms and treatment of connective tissue diseases vary depending on the type and severity of the condition. Treatment may include medications to reduce inflammation, suppress the immune system, or manage pain. In some cases, surgery may be necessary to repair or replace damaged tissues or organs.

Bleeding time is a medical test that measures the time it takes for a small blood vessel to stop bleeding after being cut. It's used to evaluate platelet function and the effectiveness of blood clotting. The most common method used to measure bleeding time is the Ivy method, which involves making a standardized incision on the forearm and measuring the time it takes for the bleeding to stop. A normal bleeding time ranges from 2 to 9 minutes, but this can vary depending on the specific method used. Prolonged bleeding time may indicate an impairment in platelet function or clotting factor deficiency.

Prostaglandins are naturally occurring, lipid-derived hormones that play various important roles in the human body. They are produced in nearly every tissue in response to injury or infection, and they have diverse effects depending on the site of release and the type of prostaglandin. Some of their functions include:

1. Regulation of inflammation: Prostaglandins contribute to the inflammatory response by increasing vasodilation, promoting fluid accumulation, and sensitizing pain receptors, which can lead to symptoms such as redness, heat, swelling, and pain.
2. Modulation of gastrointestinal functions: Prostaglandins protect the stomach lining from acid secretion and promote mucus production, maintaining the integrity of the gastric mucosa. They also regulate intestinal motility and secretion.
3. Control of renal function: Prostaglandins help regulate blood flow to the kidneys, maintain sodium balance, and control renin release, which affects blood pressure and fluid balance.
4. Regulation of smooth muscle contraction: Prostaglandins can cause both relaxation and contraction of smooth muscles in various tissues, such as the uterus, bronchioles, and vascular system.
5. Modulation of platelet aggregation: Some prostaglandins inhibit platelet aggregation, preventing blood clots from forming too quickly or becoming too large.
6. Reproductive system regulation: Prostaglandins are involved in the menstrual cycle, ovulation, and labor induction by promoting uterine contractions.
7. Neurotransmission: Prostaglandins can modulate neurotransmitter release and neuronal excitability, affecting pain perception, mood, and cognition.

Prostaglandins exert their effects through specific G protein-coupled receptors (GPCRs) found on the surface of target cells. There are several distinct types of prostaglandins (PGs), including PGD2, PGE2, PGF2α, PGI2 (prostacyclin), and thromboxane A2 (TXA2). Each type has unique functions and acts through specific receptors. Prostaglandins are synthesized from arachidonic acid, a polyunsaturated fatty acid derived from membrane phospholipids, by the action of cyclooxygenase (COX) enzymes. Nonsteroidal anti-inflammatory drugs (NSAIDs), such as aspirin and ibuprofen, inhibit COX activity, reducing prostaglandin synthesis and providing analgesic, anti-inflammatory, and antipyretic effects.

Combination drug therapy is a treatment approach that involves the use of multiple medications with different mechanisms of action to achieve better therapeutic outcomes. This approach is often used in the management of complex medical conditions such as cancer, HIV/AIDS, and cardiovascular diseases. The goal of combination drug therapy is to improve efficacy, reduce the risk of drug resistance, decrease the likelihood of adverse effects, and enhance the overall quality of life for patients.

In combining drugs, healthcare providers aim to target various pathways involved in the disease process, which may help to:

1. Increase the effectiveness of treatment by attacking the disease from multiple angles.
2. Decrease the dosage of individual medications, reducing the risk and severity of side effects.
3. Slow down or prevent the development of drug resistance, a common problem in chronic diseases like HIV/AIDS and cancer.
4. Improve patient compliance by simplifying dosing schedules and reducing pill burden.

Examples of combination drug therapy include:

1. Antiretroviral therapy (ART) for HIV treatment, which typically involves three or more drugs from different classes to suppress viral replication and prevent the development of drug resistance.
2. Chemotherapy regimens for cancer treatment, where multiple cytotoxic agents are used to target various stages of the cell cycle and reduce the likelihood of tumor cells developing resistance.
3. Cardiovascular disease management, which may involve combining medications such as angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, diuretics, and statins to control blood pressure, heart rate, fluid balance, and cholesterol levels.
4. Treatment of tuberculosis, which often involves a combination of several antibiotics to target different aspects of the bacterial life cycle and prevent the development of drug-resistant strains.

When prescribing combination drug therapy, healthcare providers must carefully consider factors such as potential drug interactions, dosing schedules, adverse effects, and contraindications to ensure safe and effective treatment. Regular monitoring of patients is essential to assess treatment response, manage side effects, and adjust the treatment plan as needed.

Platelet aggregation is the clumping together of platelets (thrombocytes) in the blood, which is an essential step in the process of hemostasis (the stopping of bleeding) after injury to a blood vessel. When the inner lining of a blood vessel is damaged, exposure of subendothelial collagen and tissue factor triggers platelet activation. Activated platelets change shape, become sticky, and release the contents of their granules, which include ADP (adenosine diphosphate).

ADP then acts as a chemical mediator to attract and bind additional platelets to the site of injury, leading to platelet aggregation. This forms a plug that seals the damaged vessel and prevents further blood loss. Platelet aggregation is also a crucial component in the formation of blood clots (thrombosis) within blood vessels, which can have pathological consequences such as heart attacks and strokes if they obstruct blood flow to vital organs.

Cardiac output is a measure of the amount of blood that is pumped by the heart in one minute. It is defined as the product of stroke volume (the amount of blood pumped by the left ventricle during each contraction) and heart rate (the number of contractions per minute). Normal cardiac output at rest for an average-sized adult is about 5 to 6 liters per minute. Cardiac output can be increased during exercise or other conditions that require more blood flow, such as during illness or injury. It can be measured noninvasively using techniques such as echocardiography or invasively through a catheter placed in the heart.

"Inhalation administration" is a medical term that refers to the method of delivering medications or therapeutic agents directly into the lungs by inhaling them through the airways. This route of administration is commonly used for treating respiratory conditions such as asthma, COPD (chronic obstructive pulmonary disease), and cystic fibrosis.

Inhalation administration can be achieved using various devices, including metered-dose inhalers (MDIs), dry powder inhalers (DPIs), nebulizers, and soft-mist inhalers. Each device has its unique mechanism of delivering the medication into the lungs, but they all aim to provide a high concentration of the drug directly to the site of action while minimizing systemic exposure and side effects.

The advantages of inhalation administration include rapid onset of action, increased local drug concentration, reduced systemic side effects, and improved patient compliance due to the ease of use and non-invasive nature of the delivery method. However, proper technique and device usage are crucial for effective therapy, as incorrect usage may result in suboptimal drug deposition and therapeutic outcomes.

Follow-up studies are a type of longitudinal research that involve repeated observations or measurements of the same variables over a period of time, in order to understand their long-term effects or outcomes. In medical context, follow-up studies are often used to evaluate the safety and efficacy of medical treatments, interventions, or procedures.

In a typical follow-up study, a group of individuals (called a cohort) who have received a particular treatment or intervention are identified and then followed over time through periodic assessments or data collection. The data collected may include information on clinical outcomes, adverse events, changes in symptoms or functional status, and other relevant measures.

The results of follow-up studies can provide important insights into the long-term benefits and risks of medical interventions, as well as help to identify factors that may influence treatment effectiveness or patient outcomes. However, it is important to note that follow-up studies can be subject to various biases and limitations, such as loss to follow-up, recall bias, and changes in clinical practice over time, which must be carefully considered when interpreting the results.

Intravenous injections are a type of medical procedure where medication or fluids are administered directly into a vein using a needle and syringe. This route of administration is also known as an IV injection. The solution injected enters the patient's bloodstream immediately, allowing for rapid absorption and onset of action. Intravenous injections are commonly used to provide quick relief from symptoms, deliver medications that are not easily absorbed by other routes, or administer fluids and electrolytes in cases of dehydration or severe illness. It is important that intravenous injections are performed using aseptic technique to minimize the risk of infection.

Platelet aggregation inhibitors are a class of medications that prevent platelets (small blood cells involved in clotting) from sticking together and forming a clot. These drugs work by interfering with the ability of platelets to adhere to each other and to the damaged vessel wall, thereby reducing the risk of thrombosis (blood clot formation).

Platelet aggregation inhibitors are often prescribed for people who have an increased risk of developing blood clots due to various medical conditions such as atrial fibrillation, coronary artery disease, peripheral artery disease, stroke, or a history of heart attack. They may also be used in patients undergoing certain medical procedures, such as angioplasty and stenting, to prevent blood clot formation in the stents.

Examples of platelet aggregation inhibitors include:

1. Aspirin: A nonsteroidal anti-inflammatory drug (NSAID) that irreversibly inhibits the enzyme cyclooxygenase, which is involved in platelet activation and aggregation.
2. Clopidogrel (Plavix): A P2Y12 receptor antagonist that selectively blocks ADP-induced platelet activation and aggregation.
3. Prasugrel (Effient): A third-generation thienopyridine P2Y12 receptor antagonist, similar to clopidogrel but with faster onset and greater potency.
4. Ticagrelor (Brilinta): A direct-acting P2Y12 receptor antagonist that does not require metabolic activation and has a reversible binding profile.
5. Dipyridamole (Persantine): An antiplatelet agent that inhibits platelet aggregation by increasing cyclic adenosine monophosphate (cAMP) levels in platelets, which leads to decreased platelet reactivity.
6. Iloprost (Ventavis): A prostacyclin analogue that inhibits platelet aggregation and causes vasodilation, often used in the treatment of pulmonary arterial hypertension.
7. Cilostazol (Pletal): A phosphodiesterase III inhibitor that increases cAMP levels in platelets, leading to decreased platelet activation and aggregation, as well as vasodilation.
8. Ticlopidine (Ticlid): An older P2Y12 receptor antagonist with a slower onset of action and more frequent side effects compared to clopidogrel or prasugrel.

A dose-response relationship in the context of drugs refers to the changes in the effects or symptoms that occur as the dose of a drug is increased or decreased. Generally, as the dose of a drug is increased, the severity or intensity of its effects also increases. Conversely, as the dose is decreased, the effects of the drug become less severe or may disappear altogether.

The dose-response relationship is an important concept in pharmacology and toxicology because it helps to establish the safe and effective dosage range for a drug. By understanding how changes in the dose of a drug affect its therapeutic and adverse effects, healthcare providers can optimize treatment plans for their patients while minimizing the risk of harm.

The dose-response relationship is typically depicted as a curve that shows the relationship between the dose of a drug and its effect. The shape of the curve may vary depending on the drug and the specific effect being measured. Some drugs may have a steep dose-response curve, meaning that small changes in the dose can result in large differences in the effect. Other drugs may have a more gradual dose-response curve, where larger changes in the dose are needed to produce significant effects.

In addition to helping establish safe and effective dosages, the dose-response relationship is also used to evaluate the potential therapeutic benefits and risks of new drugs during clinical trials. By systematically testing different doses of a drug in controlled studies, researchers can identify the optimal dosage range for the drug and assess its safety and efficacy.

Isoxazoles are not a medical term, but a chemical compound. They are organic compounds containing a five-membered ring consisting of one nitrogen atom, one oxygen atom, and three carbon atoms. Isoxazoles have various applications in the pharmaceutical industry as they can be used to synthesize different drugs. Some isoxazole derivatives have been studied for their potential medicinal properties, such as anti-inflammatory, analgesic, and antipyretic effects. However, isoxazoles themselves are not a medical diagnosis or treatment.

Epoprostenol receptors, also known as prostaglandin I2 (PGI2) receptors, are a type of G protein-coupled receptor that bind to and are activated by the endogenous prostaglandin Epoprostenol. These receptors play a crucial role in regulating various physiological functions, including vasodilation, inhibition of platelet aggregation, and bronchodilation.

Epoprostenol is a potent vasodilator that acts by relaxing the smooth muscle cells in the walls of blood vessels, leading to an increase in blood flow and a decrease in blood pressure. It also inhibits platelet aggregation, which helps prevent the formation of blood clots. Additionally, epoprostenol can cause bronchodilation, or relaxation of the muscles in the airways, making it useful in the treatment of pulmonary hypertension.

Epoprostenol receptors are found in various tissues throughout the body, including the vascular endothelium, platelets, and lung tissue. Activation of these receptors leads to a cascade of intracellular signaling events that ultimately result in the physiological effects of epoprostenol.

In summary, Epoprostenol receptors are G protein-coupled receptors that bind to and are activated by epoprostenol, leading to vasodilation, inhibition of platelet aggregation, and bronchodilation. These receptors play a critical role in regulating various physiological functions throughout the body.

Intra-arterial infusion is a medical procedure in which a liquid medication or fluid is delivered directly into an artery. This technique is used to deliver drugs directly to a specific organ or region of the body, bypassing the usual systemic circulation and allowing for higher concentrations of the drug to reach the target area. It is often used in cancer treatment to deliver chemotherapeutic agents directly to tumors, as well as in other conditions such as severe infections or inflammation.

Intra-arterial infusions are typically administered through a catheter that is inserted into an artery, usually under the guidance of imaging techniques such as fluoroscopy, CT, or MRI. The procedure requires careful monitoring and precise control to ensure proper placement of the catheter and accurate delivery of the medication.

It's important to note that intra-arterial infusions are different from intra venous (IV) infusions, where medications are delivered into a vein instead of an artery. The choice between intra-arterial and intra-venous infusion depends on various factors such as the type of medication being used, the location of the target area, and the patient's overall medical condition.

A "Drug Administration Schedule" refers to the plan for when and how a medication should be given to a patient. It includes details such as the dose, frequency (how often it should be taken), route (how it should be administered, such as orally, intravenously, etc.), and duration (how long it should be taken) of the medication. This schedule is often created and prescribed by healthcare professionals, such as doctors or pharmacists, to ensure that the medication is taken safely and effectively. It may also include instructions for missed doses or changes in the dosage.

Right Ventricular Function refers to the ability of the right ventricle (RV) of the heart to receive and eject blood during the cardiac cycle. The right ventricle is one of the four chambers of the heart and is responsible for pumping deoxygenated blood from the body to the lungs for re-oxygenation.

Right ventricular function can be assessed by measuring various parameters such as:

1. Right Ventricular Ejection Fraction (RVEF): It is the percentage of blood that is ejected from the right ventricle during each heartbeat. A normal RVEF ranges from 45-75%.
2. Right Ventricular Systolic Function: It refers to the ability of the right ventricle to contract and eject blood during systole (contraction phase). This can be assessed by measuring the tricuspid annular plane systolic excursion (TAPSE) or tissue Doppler imaging.
3. Right Ventricular Diastolic Function: It refers to the ability of the right ventricle to relax and fill with blood during diastole (relaxation phase). This can be assessed by measuring the right ventricular inflow pattern, tricuspid valve E/A ratio, or deceleration time.
4. Right Ventricular Afterload: It refers to the pressure that the right ventricle must overcome to eject blood into the pulmonary artery. Increased afterload can impair right ventricular function.

Abnormalities in right ventricular function can lead to various cardiovascular conditions such as pulmonary hypertension, heart failure, and arrhythmias.

"Drug evaluation" is a medical term that refers to the systematic process of assessing the pharmacological, therapeutic, and safety profile of a drug or medication. This process typically involves several stages, including preclinical testing in the laboratory, clinical trials in human subjects, and post-marketing surveillance.

The goal of drug evaluation is to determine the efficacy, safety, and optimal dosage range of a drug, as well as any potential interactions with other medications or medical conditions. The evaluation process also includes an assessment of the drug's pharmacokinetics, or how it is absorbed, distributed, metabolized, and eliminated by the body.

The findings from drug evaluations are used to inform regulatory decisions about whether a drug should be approved for use in clinical practice, as well as to provide guidance to healthcare providers about how to use the drug safely and effectively.

Adenosine diphosphate (ADP) is a chemical compound that plays a crucial role in energy transfer within cells. It is a nucleotide, which consists of a adenosine molecule (a sugar molecule called ribose attached to a nitrogenous base called adenine) and two phosphate groups.

In the cell, ADP functions as an intermediate in the conversion of energy from one form to another. When a high-energy phosphate bond in ADP is broken, energy is released and ADP is converted to adenosine triphosphate (ATP), which serves as the main energy currency of the cell. Conversely, when ATP donates a phosphate group to another molecule, it is converted back to ADP, releasing energy for the cell to use.

ADP also plays a role in blood clotting and other physiological processes. In the coagulation cascade, ADP released from damaged red blood cells can help activate platelets and initiate the formation of a blood clot.

Anticoagulants are a class of medications that work to prevent the formation of blood clots in the body. They do this by inhibiting the coagulation cascade, which is a series of chemical reactions that lead to the formation of a clot. Anticoagulants can be given orally, intravenously, or subcutaneously, depending on the specific drug and the individual patient's needs.

There are several different types of anticoagulants, including:

1. Heparin: This is a naturally occurring anticoagulant that is often used in hospitalized patients who require immediate anticoagulation. It works by activating an enzyme called antithrombin III, which inhibits the formation of clots.
2. Low molecular weight heparin (LMWH): LMWH is a form of heparin that has been broken down into smaller molecules. It has a longer half-life than standard heparin and can be given once or twice daily by subcutaneous injection.
3. Direct oral anticoagulants (DOACs): These are newer oral anticoagulants that work by directly inhibiting specific clotting factors in the coagulation cascade. Examples include apixaban, rivaroxaban, and dabigatran.
4. Vitamin K antagonists: These are older oral anticoagulants that work by inhibiting the action of vitamin K, which is necessary for the formation of clotting factors. Warfarin is an example of a vitamin K antagonist.

Anticoagulants are used to prevent and treat a variety of conditions, including deep vein thrombosis (DVT), pulmonary embolism (PE), atrial fibrillation, and prosthetic heart valve thrombosis. It is important to note that anticoagulants can increase the risk of bleeding, so they must be used with caution and regular monitoring of blood clotting times may be required.

A pulmonary embolism (PE) is a medical condition that occurs when a blood clot, often formed in the deep veins of the legs (deep vein thrombosis), breaks off and travels to the lungs, blocking one or more pulmonary arteries. This blockage can lead to various symptoms such as shortness of breath, chest pain, rapid heart rate, and coughing up blood. In severe cases, it can cause life-threatening complications like low oxygen levels, hypotension, and even death if not promptly diagnosed and treated with anticoagulant medications or thrombolytic therapy to dissolve the clot.

Oral administration is a route of giving medications or other substances by mouth. This can be in the form of tablets, capsules, liquids, pastes, or other forms that can be swallowed. Once ingested, the substance is absorbed through the gastrointestinal tract and enters the bloodstream to reach its intended target site in the body. Oral administration is a common and convenient route of medication delivery, but it may not be appropriate for all substances or in certain situations, such as when rapid onset of action is required or when the patient has difficulty swallowing.

Angiography is a medical procedure in which an x-ray image is taken to visualize the internal structure of blood vessels, arteries, or veins. This is done by injecting a radiopaque contrast agent (dye) into the blood vessel using a thin, flexible catheter. The dye makes the blood vessels visible on an x-ray image, allowing doctors to diagnose and treat various medical conditions such as blockages, narrowing, or malformations of the blood vessels.

There are several types of angiography, including:

* Cardiac angiography (also called coronary angiography) - used to examine the blood vessels of the heart
* Cerebral angiography - used to examine the blood vessels of the brain
* Peripheral angiography - used to examine the blood vessels in the limbs or other parts of the body.

Angiography is typically performed by a radiologist, cardiologist, or vascular surgeon in a hospital setting. It can help diagnose conditions such as coronary artery disease, aneurysms, and peripheral arterial disease, among others.

Retrospective studies, also known as retrospective research or looking back studies, are a type of observational study that examines data from the past to draw conclusions about possible causal relationships between risk factors and outcomes. In these studies, researchers analyze existing records, medical charts, or previously collected data to test a hypothesis or answer a specific research question.

Retrospective studies can be useful for generating hypotheses and identifying trends, but they have limitations compared to prospective studies, which follow participants forward in time from exposure to outcome. Retrospective studies are subject to biases such as recall bias, selection bias, and information bias, which can affect the validity of the results. Therefore, retrospective studies should be interpreted with caution and used primarily to generate hypotheses for further testing in prospective studies.

I'm sorry for any confusion, but "Japan" is not a medical term. Japan is the name of a country, officially known as Nippon-koku or Nihon-koku in Japanese, and is located in East Asia. It is an island nation in the Pacific Ocean with a population of about 126 million people.

If you have any medical questions or terms that you would like me to define, please let me know!

Medical survival rate is a statistical measure used to determine the percentage of patients who are still alive for a specific period of time after their diagnosis or treatment for a certain condition or disease. It is often expressed as a five-year survival rate, which refers to the proportion of people who are alive five years after their diagnosis. Survival rates can be affected by many factors, including the stage of the disease at diagnosis, the patient's age and overall health, the effectiveness of treatment, and other health conditions that the patient may have. It is important to note that survival rates are statistical estimates and do not necessarily predict an individual patient's prognosis.

... to the Oral Endothelin Receptor Antagonist Bosentan in Patients With Pulmonary ... Cite this: Transition From Epoprostenol and Treprostinil to the Oral Endothelin Receptor Antagonist Bosentan in Patients With ... The recent development and release of the endothelin receptor antagonist bosentan has changed the approach to first line of ... Treatment with continuous IV epoprostenol, a prostacyclin, has resulted in a substantial (twofold to threefold) improvement in ...
It selectively activates the prostacyclin receptor (ie, IP-receptor), one of five types of prostanoid receptors. Unlike ... but are otherwise similar to epoprostenol. Compared with epoprostenol, treprostinil has gained more widespread use, largely ... Selexipag selectively activates the prostacyclin receptor (ie, IP-receptor), one of five types of prostanoid receptors. Unlike ... selexipag is selective for the IP receptor over other prostanoid receptors (ie, EP1-4, DP, FP, TP). Activating the IP receptor ...
... receptor agonist cicaprost relaxed human pulmonary artery preparations precontracted with phenylephrine [50% inhibitory ... Receptors, Epoprostenol * Receptors, Prostaglandin / drug effects* * Receptors, Prostaglandin / metabolism * Structure-Activity ... this may indicate IP receptor partial agonism coupled with TP receptor antagonism. The relaxant actions of the nonprostanoid ... The specific prostacyclin (IP) receptor agonist cicaprost relaxed human pulmonary artery preparations precontracted with ...
The objective of this study was to evaluate the effects of an epoprostenol analog, treprostinil, for management of pulmona … ... Intravenous epoprostenol is currently FDA approved for management of primary pulmonary hypertension, but it requires ... Endothelin receptor antagonists for pulmonary arterial hypertension. Liu C, Chen J, Gao Y, Deng B, Liu K. Liu C, et al. ... Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension Vallerie V McLaughlin 1 , Sean P ...
The objective of this study was to evaluate the effects of an epoprostenol analog, treprostinil, for management of pulmona … ... Intravenous epoprostenol is currently FDA approved for management of primary pulmonary hypertension, but it requires ... Endothelin receptor antagonists for pulmonary arterial hypertension. Liu C, Chen J, Gao Y, Deng B, Liu K. Liu C, et al. ... Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension Vallerie V McLaughlin 1 , Sean P ...
Its Farnesoid X Receptor (FXR) program used small-molecule FXR agonists in the treatment of liver diseases such as non- ... Under an agreement with GlaxoSmithKline, Myogen marketed Flolan (epoprostenol sodium) in the United States for the treatment of ... The deal was Gileads entry into the cell therapy market and added a chimeric antigen receptor T cell (CAR-T) therapy candidate ... Additionally, Myogen was developing (in Phase 3 studies) darusentan, also an endothelin receptor antagonist, for the potential ...
... with epoprostenol or an endothelin-receptor antagonist) can be considered. Sildenafil increases incidence of painful crises in ... The BMPR2 (bone morphogenic receptor type 2) pathway is targeted by sotatercept, a novel drug. BMPR2 is the most common gene ... Patients who are NYHA class IV at the time of therapy initiation should be started on parenteral epoprostenol plus an ERA/PDE5 ... The endothelin pathway is targeted by bosentan, ambrisentan, and macitentan, which are oral endothelin-receptor antagonists ( ...
Prostacyclin analogues (beraprost, epoprostenol, iloprost, treprostinil) and prostacyclin receptor agonists (selexipag): ... Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension. Am J Respir Crit Care Med. 2000 Nov. 162(5):1846- ... Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll ... Endothelin receptor antagonists (ambrisentan, bosentan, and macitentan): Activation of the endothelin system causes increased ...
9 These analogues include epoprostenol, iloprost and treprostinil, which target IP receptors to stimulate adenylate cyclase, ... Interestingly, these agents are not specific for the IP receptor and bind additional prostaglandin receptors that have diverse ... Selexipag is an oral selective prostacyclin-receptor agonist that was approved for use in patients with World Health ... Transition from intravenous epoprostenol to selexipag in pulmonary arterial hypertension: a word of caution. Eur Respir J 2020; ...
RECEPT EPOPROSTENOL. Entry Term(s). PGI2 Receptor PGI2 Receptors Prostacyclin Receptor Prostaglandin I2 Receptors ... Receptors, Epoprostenol Preferred Concept UI. M0100420. Registry Number. 0. Scope Note. Cell surface receptors for EPOPROSTENOL ... Receptors, Prostaglandin (1981-2003). Public MeSH Note. 2004; PROSTACYCLIN RECEPTOR (now RECEPTORS, EPOPROSTENOL) was indexed ... Receptors, Prostaglandin [D12.776.543.750.695.200.700] * Receptors, Epoprostenol [D12.776.543.750.695.200.700.299] ...
RECEPT EPOPROSTENOL. Entry Term(s). PGI2 Receptor PGI2 Receptors Prostacyclin Receptor Prostaglandin I2 Receptors ... Receptors, Epoprostenol Preferred Concept UI. M0100420. Registry Number. 0. Scope Note. Cell surface receptors for EPOPROSTENOL ... Receptors, Prostaglandin (1981-2003). Public MeSH Note. 2004; PROSTACYCLIN RECEPTOR (now RECEPTORS, EPOPROSTENOL) was indexed ... Receptors, Prostaglandin [D12.776.543.750.695.200.700] * Receptors, Epoprostenol [D12.776.543.750.695.200.700.299] ...
... epoprostenol plus bosentan, iloprost plus bosentan) except for epoprostenol plus sildenafil versus epoprostenol alone.34-37 ... ETA receptors on the endothelial cells stimulate vasoconstriction and proliferation while the ETB receptors are thought to ... Once-daily ambrisentan is an ETA receptor selective oral ERA. Receptor selectivity is thought to be more favorable promoting ... Intravenous (IV) epoprostenol is the only prostacyclin to improve survival in WHO class III and IV patients in studies compared ...
Endothelin - A receptor antagonism retards the progression of murine sickle cell nephropathy. Nath, K. A. & Katusic, Z. S., Aug ...
EP3 receptor deficiency attenuates pulmonary hypertension through suppression of Rho/TGF-β1 signaling. In: Journal of Clinical ... EP3 receptor deficiency attenuates pulmonary hypertension through suppression of Rho/TGF-β1 signaling. Journal of Clinical ... EP3 receptor deficiency attenuates pulmonary hypertension through suppression of Rho/TGF-β1 signaling. / Lu, Ankang; Zuo, ... title = "EP3 receptor deficiency attenuates pulmonary hypertension through suppression of Rho/TGF-β1 signaling", ...
Receptor N0000175261 Xedar Receptor N0000175262 Edar Receptor N0000168756 Toll-Like Receptor 1 N0000182134 Folate Receptor 1 ... Epoprostenol N0000166325 Heptachlor Epoxide N0000169382 Immunoglobulin epsilon-Chains N0000170331 Gonadotropins, Equine ... IDL N0000171274 Receptors, IgE N0000168822 Receptor, IGF Type 1 N0000168823 Receptor, IGF Type 2 N0000171297 Receptors, IgG ... Eph Family N0000168800 Receptor, EphA1 N0000168803 Receptor, EphA2 N0000168805 Receptor, EphA3 N0000168810 Receptor, EphA4 ...
"If these fail, we use an IV option - epoprostenol. Other options are sympathectomy surgery, Botox, digital nerve blocks, ... and/or endothelin receptor antagonists (bosentan or macitentan). The researchers noted that all patients underwent surgical ... followed by phosphodiesterase type 5 inhibitors such as sildenafil or endothelin receptor antagonist medications such as ...
Carica , Coagulantes , Hipertensão Arterial Pulmonar , Coagulantes/farmacologia , Epoprostenol/farmacologia , Epoprostenol/uso ... Human platelets were activated with convulxin (CVX), thrombin (THR) or protease-activated receptor (PAR) agonists, EPI, and ... Prostacyclin (PGI2) analogues (epoprostenol, treprostonil, iloprost) are the cornerstone of pulmonary arterial hypertension ( ... Platelet activation is characterized by shape change, granule secretion, activation of fibrinogen receptor (glycoprotein IIb/ ...
Epoprostenol The mean reduction of sildenafil (80 mg three times a day) bioavailability when co-administered with epoprostenol ... Patients were naïve for specific PAH therapy and the use of prostacyclin, prostacyclin analogues and endothelin receptor ... epoprostenol group compared with 13% of subjects in the epoprostenol group [see Clinical Studies (14)]. ... The effect of sildenafil on epoprostenol pharmacokinetics is not known. No significant interactions were shown with tolbutamide ...
ETA: endothelin receptor A; ETB: endothelin receptor B; ERA: endothelin receptor antagonists; cAMP: cyclic adenosine ... Epoprostenol was the earliest targeted drug used for the treatment of PAH and was marketed in Europe and the United States in ... ETA: endothelin receptor A; ETB: endothelin receptor B; ERA: endothelin receptor antagonists; cAMP: cyclic adenosine ... Selective estrogen receptor modulator. 2. 24. Recruiting. NCT03528902. Inflammation and Immunity. Anakinra. IL-1 receptor ...
Nitric oxide, epoprostenol (prostacyclin), and adenosine are short-acting, potent, and titratable vasodilators that may be used ... Other therapy that is currently under investigation includes the use of phosphodiesterase inhibitors and endothelin receptor ... Inhaled epoprostenol has demonstrated the ability to produce selective pulmonary vasodilatory effects that are similar to those ... Using right heart catheterization, a patients hemodynamic response to agents such as epoprostenol, adenosine, and inhaled ...
Receptors, Eicosanoid D12.776.543.750.75 Receptors, Epoprostenol D12.776.543.750.75.700.299 Receptors, Estradiol D12.776. ... Receptor, ErbB-2 D23.101.840.642 D23.101.140.642 Receptor, ErbB-3 D23.101.840.721 D23.101.140.721 Receptor, ErbB-4 D23.101. ... Receptor, Adenosine A1 D12.776.543.750.810.700.100 Receptor, Adenosine A2A D12.776.543.750.810.700.200.100 Receptor, Adenosine ... Receptor, Notch2 D12.776.930.670.750 D12.776.930.770.750 Receptor, PAR-1 D12.776.543.750.705.675.892.790 Receptor, Serotonin, 5 ...
... but not an endothelin receptor antagonist or epoprostenol. The two studies were identical in design and conducted ... 80% Starting Epoprostenol Dose. 30% Starting Epoprostenol Dose. 3. 60% Starting Epoprostenol Dose. 50% Starting Epoprostenol ... 40% Starting Epoprostenol Dose. 70% Starting Epoprostenol Dose. 5. 20% Starting Epoprostenol Dose. 90% Starting Epoprostenol ... 5% Starting Epoprostenol Dose. 110% Starting Epoprostenol Dose. 7. 0. 110% Starting Epoprostenol Dose + additional 5-10% ...
Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study. Am J Respir Crit Care Med 2005; 171 ... One study showed that, in carefully selected patients, the transition from i.v. epoprostenol to i.v. treprostinil was ... Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 2004; 24: 353-359. ... Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, ...
Receptors, Eicosanoid D12.776.543.750.75 Receptors, Epoprostenol D12.776.543.750.75.700.299 Receptors, Estradiol D12.776. ... Receptor, ErbB-2 D23.101.840.642 D23.101.140.642 Receptor, ErbB-3 D23.101.840.721 D23.101.140.721 Receptor, ErbB-4 D23.101. ... Receptor, Adenosine A1 D12.776.543.750.810.700.100 Receptor, Adenosine A2A D12.776.543.750.810.700.200.100 Receptor, Adenosine ... Receptor, Notch2 D12.776.930.670.750 D12.776.930.770.750 Receptor, PAR-1 D12.776.543.750.705.675.892.790 Receptor, Serotonin, 5 ...
Receptors, Eicosanoid D12.776.543.750.75 Receptors, Epoprostenol D12.776.543.750.75.700.299 Receptors, Estradiol D12.776. ... Receptor, ErbB-2 D23.101.840.642 D23.101.140.642 Receptor, ErbB-3 D23.101.840.721 D23.101.140.721 Receptor, ErbB-4 D23.101. ... Receptor, Adenosine A1 D12.776.543.750.810.700.100 Receptor, Adenosine A2A D12.776.543.750.810.700.200.100 Receptor, Adenosine ... Receptor, Notch2 D12.776.930.670.750 D12.776.930.770.750 Receptor, PAR-1 D12.776.543.750.705.675.892.790 Receptor, Serotonin, 5 ...
Receptors, Eicosanoid D12.776.543.750.75 Receptors, Epoprostenol D12.776.543.750.75.700.299 Receptors, Estradiol D12.776. ... Receptor, ErbB-2 D23.101.840.642 D23.101.140.642 Receptor, ErbB-3 D23.101.840.721 D23.101.140.721 Receptor, ErbB-4 D23.101. ... Receptor, Adenosine A1 D12.776.543.750.810.700.100 Receptor, Adenosine A2A D12.776.543.750.810.700.200.100 Receptor, Adenosine ... Receptor, Notch2 D12.776.930.670.750 D12.776.930.770.750 Receptor, PAR-1 D12.776.543.750.705.675.892.790 Receptor, Serotonin, 5 ...
Receptors, Eicosanoid D12.776.543.750.75 Receptors, Epoprostenol D12.776.543.750.75.700.299 Receptors, Estradiol D12.776. ... Receptor, ErbB-2 D23.101.840.642 D23.101.140.642 Receptor, ErbB-3 D23.101.840.721 D23.101.140.721 Receptor, ErbB-4 D23.101. ... Receptor, Adenosine A1 D12.776.543.750.810.700.100 Receptor, Adenosine A2A D12.776.543.750.810.700.200.100 Receptor, Adenosine ... Receptor, Notch2 D12.776.930.670.750 D12.776.930.770.750 Receptor, PAR-1 D12.776.543.750.705.675.892.790 Receptor, Serotonin, 5 ...
Receptors, Eicosanoid D12.776.543.750.75 Receptors, Epoprostenol D12.776.543.750.75.700.299 Receptors, Estradiol D12.776. ... Receptor, ErbB-2 D23.101.840.642 D23.101.140.642 Receptor, ErbB-3 D23.101.840.721 D23.101.140.721 Receptor, ErbB-4 D23.101. ... Receptor, Adenosine A1 D12.776.543.750.810.700.100 Receptor, Adenosine A2A D12.776.543.750.810.700.200.100 Receptor, Adenosine ... Receptor, Notch2 D12.776.930.670.750 D12.776.930.770.750 Receptor, PAR-1 D12.776.543.750.705.675.892.790 Receptor, Serotonin, 5 ...
Reduced thrombosis in Klkb1-/- mice is mediated by increased Mas receptor, prostacyclin, Sirt1, and KLF4 and decreased tissue ... MeSH Terms: Nerve Tissue Proteins, Animals, RNA, Messenger, Peptide Fragments, Mice, Angiotensin II, Epoprostenol, Mice, ... Knockout, Proto-Oncogene Proteins, Receptor, Bradykinin B2, Receptors, G-Protein-Coupled, Sulfonamides, Kruppel-Like ... Home Publications Reduced thrombosis in Klkb1-/- mice is mediated by increased Mas receptor, prostacyclin, Sirt1, and KLF4 and ...

No FAQ available that match "receptors epoprostenol"

No images available that match "receptors epoprostenol"